Shots:

• The new data from KEYNOTE-006/587/716 studies evaluate Keytruda in patients with melanoma. Patients were eligible for transition to KEYNOTE-587 for extended follow-up after KEYNOTE-006
• The exploratory 7yrs. follow-up data of the KEYNOTE-006 study showed m-OS (32.7mos. for Keytruda & 15.9mos. for ipilimumab; 7yrs. OS rates (37.8% & 25.3%), an exploratory analysis showed that Keytruda was associated with improved clinical outcomes regardless of BRAF status & 2 others
• The KEYNOTE-716 trial showed an improvement in RFS compared to PBO with a 39% reduction in risk of disease recurrence or death. At IA2, patients treated with Keytruda had a recurrence or died (14.8% vs 23.5%)

  Ref: Gilead | Image: Merck